SCOTTSDALE, Ariz., April 23, 2026 (GLOBE NEWSWIRE) — The Joint Corp. (NASDAQ: JYNT), the nation’s largest franchisor of chiropractic care through The Joint Chiropractic® network, announced it will report its 2026 first quarter financial results on Thursday, May 7, 2026, after the market close and host a conference call and simultaneous webcast at 5:00 p.m. ET that day. During the call, The Joint Corp. President and CEO Sanjiv Razdan and CFO Scott Bowman will review the Company’s financial results and provide a business update, followed by a question-and-answer session. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing (833) 630-0823 or (412) 317-1831 and asking to be joined into the ‘The Joint’ call approximately 15 minutes prior to the start time. The live webcast of...

Foreign player registration portal opens May 4, 2026; matches to be played across SSC (Colombo), R. Premadasa (Colombo), Pallekele (Kandy), and Rangiri Dambulla LAFAYETTE, Colo., April 23, 2026 (GLOBE NEWSWIRE) — urban-gro, Inc. (Nasdaq: UGRO) (“urban-gro” or the “Company”), operating through Flash Sports & Media, Inc., today noted the official announcement by Sri Lanka Cricket (“SLC”) confirming the dates, venues, and player-registration timeline for Lanka Premier League (“LPL”) Season 6. The tournament will run from July 10 to August 5, 2026, and is owned by SLC and conducted in partnership with Innovative Production Group FZ, LLC (“IPG”), the event rights holder. The Company participates in the tournament through its subsidiary, IPG under existing commercial arrangements. Season 6 — By the NumbersTournament window July...

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) — The Board of Directors of Nasdaq, Inc. (Nasdaq: NDAQ) has declared a regular quarterly dividend of $0.31 per share on the company’s outstanding common stock. The dividend is payable on June 26, 2026 to shareholders of record at the close of business on June 12, 2026. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About NasdaqNasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the infrastructure of the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying advanced technology, data, and intelligence solutions that enable our clients...

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report first quarter 2026 financial results on April 30, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.  To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and...

Recognition Follows FDA 510(k) Clearance of its Next-Generation Hybrid Intravascular Imaging System TORONTO, April 23, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (“Conavi” or the “Company”) (TSXV: CNVI; OTCQB: CNVIF), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has been named a recipient of a 2026 TAG Award, recognizing innovation and leadership in advancing healthcare technology. The award comes during a pivotal week for the Company, following its recent U.S. Food and Drug Administration (FDA) 510(k) clearance of its next-generation hybrid intravascular imaging system (see full announcement here). The system integrates intravascular ultrasound (IVUS) and optical coherence tomography...

Introducing the first exchange-cleared benchmark to hedge solar output variability in Europe’s largest power market TORONTO, April 23, 2026 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, indirect majority shareholder of Abaxx Singapore Pte Ltd. (“Abaxx Singapore”), the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), today announced that trading has commenced in Enwex Germany Solar (GSM) futures, extending its suite of weather-indexed benchmarks to include solar exposure in Europe’s largest power market. As solar capacity continues to scale across Germany, variability in irradiance is becoming a more material driver of realized output and revenue variability for market...

Independent material testing shows battery-grade graphitization level of over 96% MONTREAL, April 23, 2026 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis” or “the Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces, further to its press release dated April 21, 2026, the successful production of high quality battery-grade graphite from carbon black, using a proprietary plasma process. Of note, the carbon black used to produce the graphite was itself produced by PyroGenesis in a first-ever achievement where both a natural gas-powered and a methane-powered plasma torch acted as the sole feedstock (i.e. the gas flowing through the torch to create plasma acts as the feedstock that...

PARIS and AMSTERDAM and FORT COLLINS, Colo., April 23, 2026 (GLOBE NEWSWIRE) — Air France Industries KLM Engineering & Maintenance (AFI KLM E&M) has signed an Elite Licensed Repair Service Facility (LRSF) Agreement with Woodward to support the CFM International LEAP-1A and LEAP-1B* engines. Under this agreement, AFI KLM E&M is now authorized to deliver a full suite of maintenance, repair, and overhaul (MRO) services for Woodward components across the CFM LEAP engine family. This includes fuel controls, actuators, pumps, and valves—critical systems ensuring optimal engine performance and reliability. With a rapidly expanding global CFM LEAP engine fleet, this agreement strengthens AFI KLM E&M’s position as a CFM Premier MRO Provider, making it a key player in next-generation engine support. It also reinforces...

Genenta enters aerospace as it continues its strategic transformation into a next-generation industrial consolidator MILAN,Italy, April 23, 2026 (GLOBE NEWSWIRE) — Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that it has signed definitive agreements2 with Sòphia High Tech S.r.l., (Sòphia HT) an Italian company manufacturing critical parts for Europe’s space and defense programs. Genenta expects to fund a total of €6.0 million in two tranches. With the closing of the first tranche, Genenta will obtain a 19.9% stake, and with the closing of the second tranche, Genenta will own a 51% stake in Sòphia HT. The proceeds are expected to be deployed by Sòphia HT to materially...

Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI (the primary endpoint) in 90% of evaluable subjects (18/20) Presented initial Phase 0/1 data for RAD 202 at the American Association for Cancer Research demonstrating encouraging tumor uptake and a favorable safety profile in the lowest dose cohort Received positive recommendation from Data and Safety Monitoring Committee (DSMC) to advance RAD 202 to the next dose level Initiated two First-In-Human (FIH) clinical trials for radiotherapeutic assets RV-01 in various tumor types and RAD 402 in advanced prostate cancer SYDNEY, April 23, 2026 (GLOBE NEWSWIRE) — Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”),...